10x Genomics (TXG) Q3 2026 Earnings Call Transcript

10x Genomics reported Q3 2026 revenue of $150.7 million, up 1% year over year, and raised 2026 revenue guidance to $625 million–$635 million from $610 million–$630 million. Gross margin improved to 75% from 67%, and net loss narrowed to $19.4 million from $27.5 million; management expects about 50 Atera shipments by year-end, up from 40 previously. Offsetting the progress, instrument revenue fell 43%, and management expects gross margin to step down to the low-to-mid-60% range in Q4 as Atera shipments ramp; manufacturing, installation and customer training are near-term constraints.

Analysis

The key underwriting issue is conversion, not stated demand: manufacturing, installation and training constrain placements, while undisclosed orders make the claimed demand difficult to independently size. This can defer revenue and consumables pull-through even if customer interest is real. In the near term, reported gross margin is a poor run-rate anchor: an instrument-heavy launch mix is expected to pressure margins, and management indicates 2027 could remain below pre-launch levels before consumables scale. The positive offset is that whole-transcriptome use may simplify workflows and support higher ongoing reagent demand; however, the timing and utilization per installed Atera remain unproven. Atera could also displace legacy spatial instrument sales before its own recurring revenue offsets that gap. Sentira is best viewed initially as an adoption enabler, not a material standalone software earnings stream; compute expense, data governance and customer analysis capacity may limit the claimed reduction in workflow friction. Over 6–18 months, successful placements and repeat consumables orders would validate a stronger platform model. The contrarian risk is that AI-driven demand rhetoric pulls forward expectations while customer budgets, installation capacity and computational bottlenecks slow actual usage. Falsify the constructive thesis if placements miss the operational cadence management outlined, spatial consumables lose double-digit growth, or margin recovery fails to follow installed-base utilization.

Key Decisions for Investors

• Avoid chasing the launch narrative immediately; treat TXG as a conditional long on evidence of execution rather than order anecdotes. Reassess after the next quarterly update for actual placements, installation throughput and Atera consumables pull-through.
• For an existing TXG long, consider a defined-risk put spread through the next earnings catalyst: the principal near-term downside is further margin compression or delayed utilization, while undisclosed backlog limits visibility. Size against the possibility that launch timing slips; no price target is justified by the supplied data.
• Track three confirmation points over the next 1–3 months: Atera shipments versus the stated ramp, spatial consumables growth, and gross margin relative to the low-to-mid-60s Q4 expectation. A shipment shortfall or spatial consumables falling below double-digit growth would weaken the thesis; stronger-than-expected consumables pull-through would support adding exposure.
• Do not underwrite Sentira as a separate revenue catalyst yet. Watch for disclosed paid adoption, customer retention or measurable increases in instrument utilization before assigning software value; also monitor cloud/computing costs and customer data-security concerns.